氨曲南治疗中重度下呼吸道感染的临床疗效和经济学分析

The clinical effect and economic analysis of aztreonam while treating severe lower respiratory tract infection

目的:观察氨曲南治疗中重度下呼吸道感染的临床疗效和药物经济学分析。方法:159例中重度下呼吸道感染患者随机分为氨曲南治疗组(A组)53例,头孢匹罗对照组(B组)53例和头孢哌酮钠舒巴坦钠对照组(C组)53例,比较三组临床疗效及不良反应情况,并进行药物经济学分析。结果:ABC三组临床有效率分别为90.6%、88.7%、64.2%,A、B两组与C组比较有显著差异性(P<0.05),药物经济学分析氨曲南价格远低于头孢匹罗。结论:临床治疗中重度下呼吸道感染时,氨曲南是一个较为有效、安全、经济、合理的选择。

Objective： To observe the clinical effect and economic analysis ofaztreonam when treating severe lower respiratory tra -ct infection- Methods： Randomly divided 159 patients into aztreonam treatment group （group A）, cefpirome group （group B） and cefoperaz -one sodium and sulbactam sodium group （group C）, 53 cases in each- Comparing the clinical effect and adverse reactions meanwhile doing medicine economic analysis- Results： The clinical effective rates of the 3 groups were 90-6%, 88-7% and 64-2%- Compared with group C, there were significantly differences in group A and B- The price of aztreonam was far more less than that of cefpirome by the medicine economic analysis- Conclusion： When treating severe lower respiratory tract infection in clinical, aztreonam is an effective, safe, economic and reasonable choice-